Sodium‐glucose co‐transporter‐2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes

Wang, Yong; Xu, Ling; Yuan, Linhong; Li, D; Zhang, Y; Zheng, Rongqin; Liu, C; Feng, Xiu; Li, Q; Ma, Jianhua

doi:10.1111/dme.13107

Cited by 25 publications

(19 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 28 newly diagnosed T2DM patients met inclusion criteria (18 in dapagliflozin group and 10 in placebo group) and were admitted to the study. As we reported, the demographic and baseline characteristics of study subjects were similar between placebo and dapagliflozin groups [ 13 ].…”

Section: Resultsmentioning

confidence: 84%

“…Dapagliflozin reduced hyperglycemia, body weight, and SBP and effectively addressed three CVD risk factors in older patients with poorly controlled T2DM and CVD [ 6 , 11 ]. However, we observed that dapagliflozin may benefit the cardiovascular system through the reduced atrial natriuretic peptide levels [ 13 ]. The smoothed blood glycemic executions might confer another protection mechanism.…”

Section: Discussionmentioning

confidence: 99%

“…The study was performed in the Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, between July 2010 and March 2012. The study was performed as described [ 13 ]. Briefly, patients with newly diagnosed or drug-naive T2DM were recruited.…”

Section: Methodsmentioning

confidence: 99%

“…However, the clinical efficacy and tolerability need full elucidation in older patients with comorbidity [ 12 ]. We recently observed that dapagliflozin may confer reduced atrial natriuretic peptide levels and improved glycemic control in patients with newly diagnosed T2DM, which may benefit the cardiovascular system [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

et al. 2016

Journal of Diabetes Research

View full text Add to dashboard Cite

Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P = 0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P = 0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P < 0.05, resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group (P = 0.034). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system.

show abstract

Section: Resultsmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

et al. 2016

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…Dose-related 24-hour urine volume and hematocrit increased minimally [ 20 ]. More recently, newly diagnosed patients with T2DM treated with SGLT2is had reduced atrial natriuretic peptide levels, which may benefit the CV system [ 23 ].…”

Section: Reviewmentioning

confidence: 99%

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Saleem

2017

Cureus

View full text Add to dashboard Cite

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial effects on the cardiovascular (CV) system which can benefit patients with heart failure in addition toT2DM. The United States Food and Drug Administration requires new diabetes mellitus therapies to show a CV safety profile. Empagliflozin was the first SGLT2i that, when added to the standard of care for patients withT2DM at high risk for CV events, showed improved CV outcomes including reduced deaths from CV causes. Evidence also exists in favor of dapagliflozin for use in patients with T2DM with CV risk factors and heart failure. This review focuses on the effects, safety, and benefits of dapagliflozin on the CV system. Clinical trials have shown that dapagliflozin improves glycemic control without variation. It is safe and well-tolerated in the general population including older patients and those with high-risk CV factors or preexisting CV disease. There may be a renal protective role by an unknown mechanism. Dapagliflozin also lowers blood pressure due to its natriuresis effect. It improves levels of visceral fat and reduces body weight, and thus ameliorates metabolic syndrome. Dapagliflozin reduces oxidative stress and may delay atherosclerosis. Recent findings indicate SGLT2is may also reduce the atrial natriuretic peptide levels. Additional trials are required to validate these benefits and further evaluate if these are class effects. Trials such as DECLARE-TIMI58 are ongoing to evaluate the CV outcomes of dapagliflozin. More research is needed to design better antihyperglycemic regimes with clinical benefits in addition to good glycemic control.

show abstract

The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

et al. 2018

View full text Add to dashboard Cite

Sodium‐glucose co‐transporter‐2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes

Abstract: This study shows the ability of sodium-glucose co-transporter-2 inhibitors to lower atrial natriuretic peptide levels and improve glycaemic control, which may benefit the cardiovascular system.

Cited by 25 publications

References 14 publications

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About